A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Latest Information Update: 20 Dec 2024
At a glance
- Drugs Gilteritinib (Primary) ; Midostaurin (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms AMLSG 28-18; HOVON 156 AML
Most Recent Events
- 17 Dec 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Oct 2025.
- 14 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Apr 2023 This trial has been suspended in Finland, according to European Clinical Trials Database record.